Rocket Pharmaceuticals (RCKT) Short Interest Ratio & Short Volume $10.74 +0.05 (+0.47%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$10.64 -0.11 (-0.98%) As of 01/31/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Rocket Pharmaceuticals Short Interest DataRocket Pharmaceuticals (RCKT) has a short interest of 11.70 million shares. This marks a -9.51% decrease in short interest from the previous month. The short interest ratio (days to cover) is 9.0, indicating that it would take 9.0 days of the average trading volume of 1.43 million shares to cover all short positions.Current Short Interest11,700,000 sharesPrevious Short Interest12,930,000 sharesChange Vs. Previous Month-9.51%Dollar Volume Sold Short$127.30 millionShort Interest Ratio9.0 Days to CoverLast Record DateJanuary 15, 2025Outstanding Shares91,160,000 sharesPercentage of Shares Shorted12.83%Today's Trading Volume1,822,235 sharesAverage Trading Volume1,431,558 sharesToday's Volume Vs. Average127% Short Selling Rocket Pharmaceuticals? Sign up to receive the latest short interest report for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRCKT Short Interest Over TimeRCKT Days to Cover Over TimeRCKT Percentage of Float Shorted Over Time Rocket Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/15/202511,700,000 shares $127.30 million -9.5%N/A9 $10.88 12/31/202412,930,000 shares $162.53 million +15.7%N/A11.3 $12.57 12/15/202411,180,000 shares $134.38 million +7.6%N/A10.4 $12.02 11/30/202410,390,000 shares $149.51 million -6.3%N/A11.2 $14.39 11/15/202411,090,000 shares $155.04 million -6.8%N/A12.1 $13.98 10/31/202411,900,000 shares $198.14 million +3.3%N/A14.3 $16.65 10/15/202411,520,000 shares $192.15 million +1.1%N/A13.5 $16.68 9/30/202411,400,000 shares $210.56 million +1.2%N/A13.1 $18.47 9/15/202411,260,000 shares $221.26 million +3.0%N/A13 $19.65 8/31/202410,930,000 shares $206.03 million +0.1%N/A13.1 $18.85 Get the Latest News and Ratings for RCKT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rocket Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/15/202410,920,000 shares $203.11 million +3.7%N/A13 $18.60 7/31/202410,530,000 shares $254.83 million +9.2%N/A13 $24.20 7/15/20249,640,000 shares $217.38 million +14.6%N/A12.1 $22.55 6/30/20248,410,000 shares $181.07 million -9.2%N/A10.7 $21.53 6/15/20249,260,000 shares $202.42 million -1.6%N/A13.1 $21.86 5/31/20249,410,000 shares $200.62 million -5.8%N/A14.2 $21.32 5/15/20249,990,000 shares $236.36 million +1.5%N/A14.6 $23.66 4/30/20249,840,000 shares $211.76 million -10.6%N/A13.5 $21.52 4/15/202411,000,000 shares $264.11 million +4.6%N/A15.3 $24.01 3/31/202410,520,000 shares $283.41 million +2.7%N/A14.7 $26.94 3/15/202410,240,000 shares $274.53 million +2.8%N/A13.6 $26.81 2/29/20249,960,000 shares $291.83 million +8.3%N/A12 $29.30 2/15/20249,200,000 shares $280.78 million +8.9%N/A11.3 $30.52 1/31/20248,450,000 shares $242.77 million +2.4%N/A10.4 $28.73 1/15/20248,250,000 shares $236.03 million -4.2%N/A9.3 $28.61 12/31/20238,610,000 shares $258.04 million -6.5%N/A9.7 $29.97 12/15/20239,210,000 shares $260.74 million +0.9%N/A10 $28.31 11/30/20239,130,000 shares $213.00 million +0.4%N/A6.7 $23.33 11/15/20239,090,000 shares $198.53 million +0.4%N/A7 $21.84 10/31/20239,050,000 shares $163.81 million +0.7%N/A7.2 $18.10 10/15/20238,990,000 shares $157.77 million -6.5%N/A7.6 $17.55 9/30/20239,610,000 shares $196.91 million +6.7%N/A8.3 $20.49 9/15/20239,010,000 shares $211.28 million +24.5%N/A8.2 $23.45 8/31/20237,240,000 shares $113.31 million -6.2%N/A12 $15.65 8/15/20237,720,000 shares $125.37 million -1.0%N/A11.9 $16.24 7/31/20237,800,000 shares $140.79 million -2.1%N/A11.6 $18.05 7/15/20237,970,000 shares $157.17 million -2.9%N/A11.6 $19.72 6/30/20238,210,000 shares $163.13 million -1.9%N/A11.8 $19.87 6/15/20238,370,000 shares $190.42 million +6.0%N/A10.9 $22.75 5/31/20237,900,000 shares $165.35 million -2.5%N/A9.7 $20.93Alert: DOGE goes live (Ad)"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.Click here to learn more. 5/15/20238,100,000 shares $176.34 million +0.9%N/A9.8 $21.77 4/30/20238,030,000 shares $143.90 million -2.3%N/A9.6 $17.92 4/15/20238,220,000 shares $146.64 million -9.3%N/A9.7 $17.84 3/31/20239,060,000 shares $155.20 million +1.5%N/A10.5 $17.13 3/15/20238,930,000 shares $160.83 million +7.5%N/A9.5 $18.01 2/28/20238,310,000 shares $159.64 million +9.9%N/A9.2 $19.21 2/15/20237,560,000 shares $148.33 million +11.0%N/A8.6 $19.62 1/31/20236,810,000 shares $147.98 million -8.1%N/A7.5 $21.73 1/15/20237,410,000 shares $165.76 million +5.3%N/A8.1 $22.37 12/30/20227,040,000 shares $137.77 million +0.1%N/A7.7 $19.57 12/15/20227,030,000 shares $154.80 million -7.9%N/A6.8 $22.02 11/30/20227,630,000 shares $144.05 million -2.3%N/A7.6 $18.88 11/15/20227,810,000 shares $161.67 million -16.9%N/A7.8 $20.70 10/31/20229,400,000 shares $175.40 million -0.5%N/A9.7 $18.66 10/15/20229,450,000 shares $154.41 million -16.4%15.5%9.7 $16.34 9/30/202211,300,000 shares $180.35 million -3.9%18.5%11.7 $15.96 9/15/202211,760,000 shares $183.22 million +8.3%19.2%13.5 $15.58 8/31/202210,860,000 shares $167.35 million +1.1%17.8%14.2 $15.41 8/15/202210,740,000 shares $196.76 million +18.9%17.6%13.1 $18.32 7/31/20229,030,000 shares $130.94 million +5.2%14.8%9.8 $14.50 7/15/20228,580,000 shares $138.31 million +4.0%14.1%9.7 $16.12 6/30/20228,250,000 shares $113.52 million +4.2%13.6%9.7 $13.76 6/15/20227,920,000 shares $86.96 million -4.6%13.0%10.2 $10.98 5/31/20228,300,000 shares $98.36 million +10.1%13.7%12 $11.85 5/15/20227,540,000 shares $68.54 million -0.3%12.4%12.9 $9.09 4/30/20227,560,000 shares $77.72 million -12.6%12.6%15.2 $10.28 4/15/20228,650,000 shares $117.29 million -1.3%14.5%18.3 $13.56 3/31/20228,760,000 shares $138.93 million +3.8%14.7%19.2 $15.86 3/15/20228,440,000 shares $116.30 million +2.1%14.1%15.7 $13.78 2/28/20228,270,000 shares $147.29 million +1.2%14.0%15.2 $17.81 2/15/20228,170,000 shares $163.40 million +4.6%13.8%15.2 $20.00 1/31/20227,810,000 shares $129.96 million -9.2%13.8%14.5 $16.64 1/15/20228,600,000 shares $161.42 million +9.3%14.1%17 $18.77 12/31/20217,870,000 shares $171.80 million -2.6%12.9%16.9 $21.83 12/15/20218,080,000 shares $186.73 million +4.5%13.2%20.6 $23.11 11/30/20217,730,000 shares $188.84 million +0.7%12.6%22.2 $24.43 11/15/20217,680,000 shares $198.91 million -2.5%12.5%20.8 $25.90 10/29/20217,880,000 shares $234.11 million +0.9%12.8%20 $29.71 10/15/20217,810,000 shares $218.06 million -3.6%12.7%18.4 $27.92 9/30/20218,100,000 shares $242.11 million +2.4%13.1%17.6 $29.89 9/15/20217,910,000 shares $269.34 million +0.1%12.8%16.9 $34.05 8/31/20217,900,000 shares $270.26 million +2.3%12.8%17.2 $34.21 8/13/20217,720,000 shares $230.98 million -3.7%12.7%18.7 $29.92 7/30/20218,020,000 shares $287.28 million +5.3%13.2%20.4 $35.82 7/15/20217,620,000 shares $326.90 million -0.4%12.6%21.2 $42.90 6/30/20217,650,000 shares $338.82 million -4.0%12.6%21.8 $44.29 6/15/20217,970,000 shares $370.61 million -1.1%13.1%20.1 $46.50 5/28/20218,060,000 shares $342.55 million -1.0%13.3%18.6 $42.50 5/14/20218,140,000 shares $333.25 million +2.3%N/A17.3 $40.94 4/30/20217,960,000 shares $368.15 million -3.2%N/A16 $46.25Alert: DOGE goes live (Ad)"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what he might do next. And one widely followed Boston based think tank is stepping forward with their official playbook.Click here to learn more. 4/15/20218,220,000 shares $357.82 million -6.7%N/A16.7 $43.53 3/31/20218,810,000 shares $381.83 million +7.2%N/A17.3 $43.34 3/15/20218,220,000 shares $440.76 million -0.4%N/A15.7 $53.62 2/26/20218,250,000 shares $427.85 million +0.7%N/A11.2 $51.86 2/12/20218,190,000 shares $489.11 million -1.3%N/A11.2 $59.72 1/29/20218,300,000 shares $453.01 million +0.7%N/A11.5 $54.58 1/15/20218,240,000 shares $480.97 million +0.1%N/A11.9 $58.37 12/31/20208,230,000 shares $461.29 million -10.8%N/A12.3 $56.05 12/15/20209,230,000 shares $517.53 million +1.5%N/A14.8 $56.07 11/30/20209,090,000 shares $291.24 million -0.6%N/A19.9 $32.04 11/15/20209,140,000 shares $292.21 million -5.8%N/A30.3 $31.97 10/30/20209,700,000 shares $279.65 million +0.6%N/A35.5 $28.83 10/15/20209,640,000 shares $268.76 million +0.8%N/A34.6 $27.88 9/30/20209,560,000 shares $218.54 million +0.5%N/A32 $22.86 9/15/20209,510,000 shares $230.81 million +0.4%N/A25.9 $24.27 8/31/20209,470,000 shares $242.15 million -0.3%N/A23.1 $25.57 8/14/20209,500,000 shares $261.16 million +2.6%N/A22.1 $27.49 7/31/20209,260,000 shares $217.89 million +0.3%N/A21.1 $23.53 7/15/20209,230,000 shares $215.06 million +4.5%N/A20.6 $23.30 6/30/20208,830,000 shares $186.22 million +6.5%N/A19.8 $21.09 6/15/20208,290,000 shares $161.49 million -1.1%N/A20.8 $19.48 5/29/20208,380,000 shares $157.63 million +2.7%N/A20.4 $18.81 5/15/20208,160,000 shares $161.89 million +0.5%N/A18.7 $19.84 4/30/20208,120,000 shares $120.18 million -1.8%N/A18.5 $14.80 4/15/20208,270,000 shares $128.43 million +7.1%N/A19.6 $15.53 3/31/20207,720,000 shares $134.02 million +2.1%N/A18.3 $17.36 3/13/20207,560,300 shares $120.06 million +6.5%N/A14.1 $15.88 2/28/20207,100,000 shares $96.13 million -0.4%N/A15.4 $13.54 2/14/20207,130,000 shares $130.19 million +1.1%N/A16.7 $18.26 RCKT Short Interest - Frequently Asked Questions What is Rocket Pharmaceuticals' current short interest? Short interest is the volume of Rocket Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of January 15th, investors have sold 11,700,000 shares of RCKT short. Learn More on Rocket Pharmaceuticals' current short interest. What is a good short interest ratio for Rocket Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RCKT shares currently have a short interest ratio of 9.0. Learn More on Rocket Pharmaceuticals's short interest ratio. Which institutional investors are shorting Rocket Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Rocket Pharmaceuticals: Barclays PLC, Jane Street Group LLC, and Wolverine Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Rocket Pharmaceuticals' short interest increasing or decreasing? Rocket Pharmaceuticals saw a decline in short interest in the month of January. As of January 15th, there was short interest totaling 11,700,000 shares, a decline of 9.5% from the previous total of 12,930,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Rocket Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Rocket Pharmaceuticals: ADMA Biologics, Inc. (5.72%), Apellis Pharmaceuticals, Inc. (14.50%), Viking Therapeutics, Inc. (18.13%), Avidity Biosciences, Inc. (12.90%), PTC Therapeutics, Inc. (5.50%), Crinetics Pharmaceuticals, Inc. (7.73%), Rhythm Pharmaceuticals, Inc. (8.87%), Akero Therapeutics, Inc. (4.80%), Arcellx, Inc. (16.46%), Immunovant, Inc. (21.69%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($4.18 billion), Charter Communications, Inc. ($3.91 billion), Reddit, Inc. ($3.16 billion), The Kroger Co. ($2.75 billion), International Paper ($2.57 billion), Cencora, Inc. ($2.06 billion), SoFi Technologies, Inc. ($2.06 billion), Rivian Automotive, Inc. ($2.00 billion), Live Nation Entertainment, Inc. ($1.63 billion), and Hims & Hers Health, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Rocket Pharmaceuticals stock? Short selling RCKT is an investing strategy that aims to generate trading profit from Rocket Pharmaceuticals as its price is falling. RCKT shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Rocket Pharmaceuticals? A short squeeze for Rocket Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RCKT, which in turn drives the price of the stock up even further. How often is Rocket Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RCKT, twice per month. The most recent reporting period available is January, 15 2025. More Short Interest Resources from MarketBeat Related Companies ADMA Biologics Short Squeeze Apellis Pharmaceuticals Short Squeeze Viking Therapeutics Short Squeeze Avidity Biosciences Short Squeeze PTC Therapeutics Short Squeeze Crinetics Pharmaceuticals Short Squeeze Rhythm Pharmaceuticals Short Squeeze Akero Therapeutics Short Squeeze Arcellx Short Squeeze Immunovant Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RCKT) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rocket Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rocket Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.